Duality Biotherapeutics, Inc. (HKG:9606)

Market Cap	29.67B
Revenue (ttm)	2.38B
Net Income (ttm)	-3.10B
Shares Out	88.29M
EPS (ttm)	-124.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	662,300
Average Volume	1,004,259
Open	340.20
Previous Close	342.80
Day's Range	329.80 - 344.00
52-Week Range	165.50 - 563.50
Beta	n/a
RSI	52.63
Earnings Date	Nov 26, 2025

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 170
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9606

Financial Performance

Financial numbers in CNY